文献速递乳腺癌

诊断时血清维生素D水平与乳腺癌生存的关联:Pathways研究中的病例-队列分析

Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究基于Pathways前瞻性队列(4505例浸润性乳腺癌患者),采用病例-队列设计检测1666例诊断时血清25OHD水平。结果示25OHD最高三分位组较低三分位组总生存更优(HR 0.72,95%CI 0.54-0.98),绝经前女性关联更强(OS HR 0.45,95%CI 0.21-0.96)。

要点

  • 诊断时血清25OHD最高三分位组总生存优于最低三分位组(HR 0.72,95%CI 0.54-0.98)。
  • 绝经前女性中25OHD与总生存关联更强(HR 0.45,95%CI 0.21-0.96)。
  • 晚期肿瘤患者25OHD较低,绝经前三阴性乳腺癌患者最低。

核心结论

  • 血清25OHD水平与乳腺癌预后特征及患者预后独立相关,在绝经前女性中最显著。
  • 来自大型、特征明确的前瞻性队列的观察性证据提示维生素D与较低的乳腺癌发病率和死亡率风险相关。

研究设计与样本

  • Pathways研究为2006年建立的前瞻性队列,纳入Kaiser Permanente Northern California确诊的浸润性乳腺癌女性,总入组率46%(4505/9820),随访持续进行。
  • 采用病例-队列设计,选取1666名有血清样本的队列成员,确保亚队列中种族和临床亚型代表性。
  • 数据分析时间为2014年1月5日至2015年3月15日。

主要发现

  • 平均(SD)年龄58.7(12.4)岁。
  • 晚期肿瘤女性血清25OHD浓度较低,绝经前三阴性乳腺癌女性最低。
  • 25OHD水平与疾病进展和死亡风险呈负相关。
  • 与最低三分位相比,最高三分位25OHD女性总生存更优,调整临床预后因素后关联仍存在(HR 0.72,95%CI 0.54-0.98)。
  • 绝经前女性中,总生存关联更强(HR 0.45,95%CI 0.21-0.96),乳腺癌特异性生存(HR 0.37,95%CI 0.15-0.93)和侵袭性疾病无病生存(HR 0.58,95%CI 0.34-1.01)亦存在关联,均为完全调整后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are long-standing interests in the potential benefits of vitamin D for preventing breast cancer recurrence and mortality, yet data from prospective cohort studies are limited. OBJECTIVE: To investigate a serum biomarker of vitamin D status, 25-hydroxyvitamin D (25OHD) measured at the time of breast cancer diagnosis, to determine the association with prognosis. DESIGN, SETTING, AND PARTICIPANTS: The Pathways Study is a prospective cohort study of breast cancer survivors established in 2006. Enrollment was completed in 2013; follow-up is ongoing. The cohort was established in Kaiser Permanente Northern California, a large integrated health care delivery system in northern California. Women with a diagnosis of incident invasive breast cancer were typically consented and enrolled within 2 months of diagnosis. The overall enrollment rate was 46% (4505 of 9820). Participants are followed for health outcomes and comorbidities at 12, 24, 48, 72, and 96 months after baseline interview. A case-cohort design was used for efficiency assay of 25OHD, selecting 1666 cohort members with serum samples and ensuring representation in the subcohort of races and clinical subtypes. The data analysis was performed from January 5, 2014, to March 15, 2015. MAIN OUTCOMES AND MEASURES: Primary outcomes are breast cancer recurrence, second primary cancer, and death. RESULTS: Mean (SD) age was 58.7 (12.4) years. Serum 25OHD concentrations were lower in women with advanced-stage tumors, and the lowest in premenopausal women with triple-negative cancer. Levels were also inversely associated with hazards of disease progression and death. Compared with the lowest tertile, women with the highest tertile of 25OHD levels had superior overall survival (OS). This association remained after adjustment for clinical prognostic factors (hazard ratio [HR], 0.72; 95% CI, 0.54-0.98). Among premenopausal women, the association with OS was stronger, and there were also associations with breast cancer-specific survival and invasive disease-free survival (OS: HR, 0.45; 95% CI, 0.21-0.96; breast cancer-specific survival: HR, 0.37; 95% CI, 0.15-0.93; invasive disease-free survival: HR, 0.58; 95% CI, 0.34-1.01; all after full adjustment). CONCLUSIONS AND RELEVANCE: Serum 25OHD levels were independently associated with breast cancer prognostic characteristics and patient prognosis, most prominently among premenopausal women. Our findings from a large, well-characterized prospective cohort provide compelling observational evidence on associations of vitamin D with lower risk of breast cancer morbidity and mortality.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yao S, Kwan ML, Ergas IJ, et al. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA Oncol. 2017. PMID: 27832250. doi:10.1001/jamaoncol.2016.4188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。